In a shocking move, Danaher is set to acquire Masimo in a staggering $9.9 billion deal, marking a significant shift in the diagnostics industry. But what's the motivation behind this massive acquisition? And how will it impact the market?
Danaher, a life science giant, is gearing up to purchase Masimo, a leading manufacturer of pulse oximeters. This acquisition is a strategic play to bolster Danaher's diagnostics offerings. With a price tag of $180 per share, the deal offers a substantial 38.3% premium on Masimo's last closing price. It's a bold move, especially considering Danaher's recent history of large-scale acquisitions, including the $5.7 billion purchase of Abcam in 2023.
The life science sector has been navigating turbulent waters, facing challenges like drug pricing regulations, potential tariffs, and reduced research funding. By acquiring Masimo, Danaher aims to diversify its product range, entering the patient monitoring space with Masimo's renowned pulse oximeters. This expansion could be a game-changer, but is it a risky move in an already uncertain market?
Masimo's non-invasive oximeters will pair well with Danaher's existing Radiometer blood analyzer devices, offering a comprehensive solution. This acquisition comes at a time when Masimo is in a legal battle with Apple over patent infringement, which resulted in a $634 million verdict against Apple. Masimo's transformation into a med-tech powerhouse, after selling its audio brands to Samsung, further highlights its strategic importance.
The deal is expected to enhance Danaher's earnings, with Masimo contributing $0.15 to $0.20 per share in the first year and approximately $0.70 in the fifth year. With a market cap of $7 billion, Masimo is a substantial addition to Danaher's $150+ billion valuation. But will this acquisition pay off, or is it a gamble?
As the deal is set to close by late 2026, the industry awaits the outcome of this massive merger. What do you think? Is this a brilliant strategic move or a risky bet in a volatile market?
